MEP32208A - Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients - Google Patents

Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Info

Publication number: MEP32208A
Authority: ME; Montenegro
Prior art keywords: active ingredients; combination; agonist; lasting; beta2
Prior art date: 2003-02-27

Application number

MEP-322/08A

Other languages

Bosnian (bs)

English (en)

Inventor

Roberta Razzetti

Fiorella Pastore

Original Assignee

Chiesi Farma Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-27

Publication date

2010-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32748803&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MEP32208(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-02-27 Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa

2010-10-10 Publication of MEP32208A publication Critical patent/MEP32208A/xx

Links

239000004480 active ingredient Substances 0.000 title abstract 4
229940124748 beta 2 agonist Drugs 0.000 title abstract 2
230000005923 long-lasting effect Effects 0.000 title abstract 2
239000003814 drug Substances 0.000 title 1
230000003389 potentiating effect Effects 0.000 title 1
229940124630 bronchodilator Drugs 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 abstract 1
208000019693 Lung disease Diseases 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
239000000168 bronchodilator agent Substances 0.000 abstract 1
230000001684 chronic effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MEP-322/08A 2003-02-27 2004-02-27 Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients MEP32208A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP03004184A EP1452179A1 (en)	2003-02-27	2003-02-27	Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
PCT/EP2004/001960 WO2004075896A1 (en)	2003-02-27	2004-02-27	Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
YUP-2005/0615A RS20050615A (sr)	2003-02-27	2004-02-27	Lek koji sadrži visoko potentni dugotrajni beta2-agonist u kombinaciji sa drugim aktivnim sastojcima

Publications (1)

Publication Number	Publication Date
MEP32208A true MEP32208A (en)	2010-10-10

Family

ID=32748803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-322/08A MEP32208A (en)	2003-02-27	2004-02-27	Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients

Country Status (31)

Country	Link
US (1)	US20070020190A1 (pl)
EP (3)	EP1452179A1 (pl)
JP (1)	JP2006519204A (pl)
KR (1)	KR20050104367A (pl)
CN (2)	CN100370986C (pl)
AR (1)	AR043419A1 (pl)
AT (1)	ATE401887T1 (pl)
AU (1)	AU2004216472B2 (pl)
BR (1)	BRPI0408047A (pl)
CA (1)	CA2517321A1 (pl)
CY (1)	CY1108360T1 (pl)
DE (1)	DE602004015260D1 (pl)
DK (1)	DK1603565T3 (pl)
EA (1)	EA008828B1 (pl)
ES (1)	ES2309503T3 (pl)
HR (1)	HRP20050726A2 (pl)
MA (1)	MA27630A1 (pl)
ME (1)	MEP32208A (pl)
MX (1)	MXPA05009007A (pl)
NO (1)	NO20053959L (pl)
NZ (1)	NZ541997A (pl)
PE (1)	PE20050290A1 (pl)
PL (1)	PL377814A1 (pl)
PT (1)	PT1603565E (pl)
RS (1)	RS20050615A (pl)
SA (1)	SA04250122B1 (pl)
SI (1)	SI1603565T1 (pl)
TN (1)	TNSN05186A1 (pl)
UA (1)	UA82217C2 (pl)
WO (1)	WO2004075896A1 (pl)
ZA (1)	ZA200506820B (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20060257324A1 (en) *	2000-05-22	2006-11-16	Chiesi Farmaceutici S.P.A.	Pharmaceutical solution formulations for pressurised metered dose inhalers
JP2007500676A (ja) *	2003-07-31	2007-01-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗コリン作用薬とベータ受容体刺激薬を含む吸入用薬剤
EP1654001A2 (en) *	2003-08-05	2006-05-10	Boehringer Ingelheim International GmbH	Medicaments for inhalation comprising steroids and a betamimetic
US8371292B2 (en) *	2003-09-16	2013-02-12	Nycomed Gmbh	Use of ciclesonide for the treatment of respiratory diseases
MX2007011273A (es) *	2005-03-16	2007-11-08	Meda Pharma Gmbh & Co Kg	La combinacion de anticolinergicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias.
WO2006105401A2 (en) *	2005-03-30	2006-10-05	Schering Corporation	Medicaments and methods combining an anticholinergic, a corticosteroid, and a long acting beta agonist
AU2006275137A1 (en) *	2005-08-01	2007-02-08	Chiesi Farmaceutici S.P.A.	Pharmaceutical formulations comprising a long-acting beta2-agonist for administration by nebulisation
WO2007058971A2 (en)	2005-11-10	2007-05-24	Bodor Nicholas S	Soft anticholinergic esters
WO2007071313A2 (en) *	2005-12-21	2007-06-28	Meda Pharma Gmbh & Co Kg	Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases
EP2029127A1 (en) *	2006-05-24	2009-03-04	Boehringer Ingelheim International GmbH	New long-acting drug combinations for the treatment of respiratory diseases
EP1953143A1 (en) *	2007-01-30	2008-08-06	CHIESI FARMACEUTICI S.p.A.	Process for the preparation of 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride
WO2008102128A2 (en) *	2007-02-19	2008-08-28	Cipla Limited	Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
ES2394589T3 (es)	2007-12-14	2013-02-04	Aerodesigns, Inc	Suministro de productos alimenticios transformables en aerosol
EP2100598A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
WO2010013240A1 (en) *	2008-07-31	2010-02-04	Dekel Pharmaceuticals Ltd.	Compositions and methods for treating inflammatory disorders
WO2010097188A1 (en) *	2009-02-25	2010-09-02	Chiesi Farmaceutici S.P.A.	Inhalation particles comprising a salt of carmoterol and a corticosteroid
KR20120023663A (ko) *	2009-05-25	2012-03-13	키에시 파르마슈티시 엣스. 피. 에이.	폐 계면활성제 및 스테로이드를 포함하는 치료적 조합
AU2010253770B9 (en)	2009-05-29	2015-02-12	Pearl Therapeutics, Inc.	Compositions for respiratory delivery of active agents and associated methods and systems
AU2015201037C1 (en) *	2009-05-29	2017-07-27	Pearl Therapeutics, Inc.	Respiratory delivery of active agents
WO2011136753A1 (en) *	2010-04-26	2011-11-03	Mahmut Bilgic	Combination of carmoterol and fluticasone for use in the treatment respiratory diseases
CN102247597B (zh) *	2010-05-19	2015-01-07	天津金耀集团有限公司	一种糖皮质激素与支气管扩张剂的吸入剂
JP2013531056A (ja) *	2010-07-16	2013-08-01	シプラ・リミテッド	Ｒ（＋）ブデソニド及び１以上の気管支拡張剤を含む医薬組成物
WO2012010854A1 (en)	2010-07-23	2012-01-26	Cipla Limited	Inhalation formulations comprising carmoterol in combination with a corticosteroid
CN102416179B (zh) *	2010-09-28	2014-05-07	益得生物科技股份有限公司	用于哮喘的吸入性复方组合物
TWI399202B (zh) *	2011-03-17	2013-06-21	Intech Biopharm Ltd	製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法
EP2510928A1 (en)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium for use in improving the quality of sleep in respiratory patients
SI2968313T1 (en) *	2013-03-15	2018-05-31	Verona Pharma Plc	Combination of medicines
WO2016044370A1 (en)	2014-09-16	2016-03-24	India Globalization Capital, Inc.	Cannabinoid composition and method for treating pain
WO2016085933A1 (en) *	2014-11-24	2016-06-02	The Board Of Trustees Of The University Of Illinois	Method of preventing or treating a pulmonary disease or condition
WO2016118391A1 (en)	2015-01-25	2016-07-28	India Globalization Capital, Inc.	Composition and method for treating seizure disorders
US10596159B2 (en)	2015-08-12	2020-03-24	India Globalization Capital, Inc.	Method and composition for treating cachexia and eating disorders
WO2017218629A1 (en)	2016-06-15	2017-12-21	India Globalization Capital, Inc.	Method and composition for treating seizure disorders
CN115337311B (zh) *	2022-09-26	2023-05-09	南京恒道医药科技股份有限公司	一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5874063A (en) *	1991-04-11	1999-02-23	Astra Aktiebolag	Pharmaceutical formulation
SE9700135D0 (sv) *	1997-01-20	1997-01-20	Astra Ab	New formulation
DE69828155T2 (de) *	1997-03-20	2005-12-22	Schering Corp.	Herstellung von pulveragglomeraten
IT1303788B1 (it) *	1998-11-25	2001-02-23	Chiesi Farma Spa	Formulazioni di aerosol medicinali.
US20020081266A1 (en) *	1999-08-20	2002-06-27	Norton Healthcare Ltd.	Spray dried powders for pulmonary or nasal administration
PE20011227A1 (es) *	2000-04-17	2002-01-07	Chiesi Farma Spa	Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
JP5392880B2 (ja) *	2000-05-22	2014-01-22	キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ	加圧式定量吸入器のための安定な製薬学的溶液製剤
EP1340492A1 (en) *	2002-03-01	2003-09-03	CHIESI FARMACEUTICI S.p.A.	Aerosol formulations for pulmonary administration of medicaments having systemic effects
IL163843A0 (en) *	2002-03-01	2005-12-18	Chiesi Farma Spa	Formoterol superfine formulation
EP1595531A1 (en) *	2004-05-13	2005-11-16	CHIESI FARMACEUTICI S.p.A.	Stable pharmaceutical solution formulations for pressurized metered dose inhalers

2003
- 2003-02-27 EP EP03004184A patent/EP1452179A1/en not_active Withdrawn
2004
- 2004-02-26 PE PE2004000199A patent/PE20050290A1/es not_active Application Discontinuation
- 2004-02-27 PL PL377814A patent/PL377814A1/pl not_active Application Discontinuation
- 2004-02-27 CN CNB2004800053713A patent/CN100370986C/zh not_active Expired - Fee Related
- 2004-02-27 PT PT04715295T patent/PT1603565E/pt unknown
- 2004-02-27 AU AU2004216472A patent/AU2004216472B2/en not_active Ceased
- 2004-02-27 EP EP04715295A patent/EP1603565B1/en not_active Expired - Lifetime
- 2004-02-27 ES ES04715295T patent/ES2309503T3/es not_active Expired - Lifetime
- 2004-02-27 ZA ZA200506820A patent/ZA200506820B/en unknown
- 2004-02-27 RS YUP-2005/0615A patent/RS20050615A/sr unknown
- 2004-02-27 KR KR1020057014683A patent/KR20050104367A/ko not_active Ceased
- 2004-02-27 JP JP2006501966A patent/JP2006519204A/ja active Pending
- 2004-02-27 BR BRPI0408047-5A patent/BRPI0408047A/pt not_active IP Right Cessation
- 2004-02-27 CA CA002517321A patent/CA2517321A1/en not_active Abandoned
- 2004-02-27 MX MXPA05009007A patent/MXPA05009007A/es active IP Right Grant
- 2004-02-27 UA UAA200507796A patent/UA82217C2/uk unknown
- 2004-02-27 US US10/546,619 patent/US20070020190A1/en not_active Abandoned
- 2004-02-27 WO PCT/EP2004/001960 patent/WO2004075896A1/en not_active Ceased
- 2004-02-27 CN CNA2007101120284A patent/CN101244063A/zh active Pending
- 2004-02-27 ME MEP-322/08A patent/MEP32208A/xx unknown
- 2004-02-27 SI SI200430815T patent/SI1603565T1/sl unknown
- 2004-02-27 EA EA200501108A patent/EA008828B1/ru not_active IP Right Cessation
- 2004-02-27 EP EP07009204A patent/EP1834643A3/en not_active Withdrawn
- 2004-02-27 DK DK04715295T patent/DK1603565T3/da active
- 2004-02-27 DE DE602004015260T patent/DE602004015260D1/de not_active Expired - Lifetime
- 2004-02-27 HR HR20050726A patent/HRP20050726A2/xx not_active Application Discontinuation
- 2004-02-27 AT AT04715295T patent/ATE401887T1/de not_active IP Right Cessation
- 2004-02-27 AR ARP040100620A patent/AR043419A1/es not_active Application Discontinuation
- 2004-02-27 NZ NZ541997A patent/NZ541997A/en unknown
- 2004-05-19 SA SA04250122A patent/SA04250122B1/ar unknown
2005
- 2005-07-29 TN TNP2005000186A patent/TNSN05186A1/en unknown
- 2005-08-25 NO NO20053959A patent/NO20053959L/no not_active Application Discontinuation
- 2005-09-06 MA MA28483A patent/MA27630A1/fr unknown
2008
- 2008-09-19 CY CY20081101023T patent/CY1108360T1/el unknown

Also Published As

Publication number	Publication date
HK1087009A1 (en)	2006-10-06
EA008828B1 (ru)	2007-08-31
EP1603565A1 (en)	2005-12-14
SI1603565T1 (sl)	2008-10-31
CA2517321A1 (en)	2004-09-10
ZA200506820B (en)	2006-11-29
DK1603565T3 (da)	2008-11-10
US20070020190A1 (en)	2007-01-25
PE20050290A1 (es)	2005-05-26
KR20050104367A (ko)	2005-11-02
BRPI0408047A (pt)	2006-02-14
CY1108360T1 (el)	2014-02-12
SA04250122B1 (ar)	2009-03-11
CN100370986C (zh)	2008-02-27
AR043419A1 (es)	2005-07-27
NZ541997A (en)	2008-12-24
AU2004216472A1 (en)	2004-09-10
EP1834643A3 (en)	2007-10-24
NO20053959D0 (no)	2005-08-25
NO20053959L (no)	2005-11-28
MA27630A1 (fr)	2005-11-01
PT1603565E (pt)	2008-10-06
AU2004216472B2 (en)	2009-08-06
EA200501108A1 (ru)	2006-04-28
EP1452179A1 (en)	2004-09-01
CN101244063A (zh)	2008-08-20
EP1834643A2 (en)	2007-09-19
HRP20050726A2 (en)	2006-02-28
DE602004015260D1 (de)	2008-09-04
MXPA05009007A (es)	2005-10-18
UA82217C2 (uk)	2008-03-25
PL377814A1 (pl)	2006-02-20
EP1603565B1 (en)	2008-07-23
WO2004075896A1 (en)	2004-09-10
CN1753678A (zh)	2006-03-29
TNSN05186A1 (en)	2007-06-11
RS20050615A (sr)	2007-09-21
JP2006519204A (ja)	2006-08-24
ES2309503T3 (es)	2008-12-16
ATE401887T1 (de)	2008-08-15

Publication	Publication Date	Title
HRP20050726A2 (en)	2006-02-28	Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients
WO2021207409A3 (en)	2021-12-09	Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
FI20002215A0 (fi)	2000-10-06	Yhdistelmäpartikkelit
BRPI0110947B8 (pt)	2021-05-25	processo para a preparação de uma composição farmacêutica e composição farmacêutica assim obtida
DE60120648D1 (de)	2006-07-27	Formulierungen von copolymer 1 (glatirameracetat) zur oralen, nasalen und pulmonalen verabreichung
WO2002083079A3 (en)	2003-02-13	Aerosol compositions containing formoterol for delivery to the lungs via nebulization
EA200501268A1 (ru)	2006-02-24	Ингибирующие вич 1,2,4-триазины
WO2005115406A3 (en)	2006-08-03	8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
ATE450250T1 (de)	2009-12-15	Stabile zusammensetzung enhaltend partikel in einer gefrorenen wässrigen matrix
HRP20080439T3 (hr)	2008-10-31	Nova kombinacija antikolinergika i beta mimetika za liječenje respiratornih bolesti
CL2003002746A1 (es)	2005-02-11	Compuesto derivado de piridazin-3(2h)-ona sustituida en las posiciones 4,5,6; procedimiento de preparacion de dicho compuesto; compuesto intermediario; composicion farmaceutica; y el uso del compuesto para el tratamiento del asma, enfermedad pulmonar
UA84048C2 (ru)	2008-09-10	Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
ATE398999T1 (de)	2008-07-15	Aerosol-formulierungen von formoterol und mometason
BR0210473A (pt)	2004-08-10	Composição compreendendo um inibidor da pde-4 e antagonista do receptor-h1 e seus usos na produção de um medicamento para o tratamento de doenças respiratórias
YU58398A (en)	1999-11-22	Combinations comprising vx478, zidovudine, ftc and/or 3tc for use the terapy of hiv
NO20080950L (no)	2008-05-26	Topiske formuleringer inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
WO2005025498A3 (en)	2008-11-27	Substituted acetanilides and benzamides for the treatment of asthma and pulmonary inflammation
WO2005041922A3 (en)	2005-09-15	Composition
WO2005011616A3 (en)	2007-02-22	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
WO2005011595A3 (en)	2007-08-02	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
UY28096A1 (es)	2004-06-30	Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación
MEP39708A (en)	2011-02-10	New pharmaceutical compositions containing epinastine and pseudoephedrine
WO2005011615A3 (en)	2007-04-19	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
WO2005011603A3 (en)	2007-05-18	Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a beta-agonist bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
ATE369121T1 (de)	2007-08-15	Bimodale trockenpulverzusammensetzung zur inhalation